I agree with Geeenius. The snag with the FDA did hurt, but Vivagel is still going out to the rest of the world and the DEP technology is still progressing into new products with big potential markets. It is all developing MUCH slower than I guessed when I bought my 1st stock 10 years ago, but Dr JF has changed SPL from a company with one major product aimed at Hepatitis and HIV (a legally risk-prone labeling which she rightly steered away from) to one rolling multi-product innovations. JF has done well within her scope. The company is slowly progressing. SPL needs expertise with the FDA and seems to be seeking it. I think all is headed the right direction, I just wish SPL would turn into a profitable company and build a buffer to stand the storm that will soon take down many companies (when money will not be available to borrow).
SPL Price at posting:
$1.17 Sentiment: Buy Disclosure: Held
